These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37558171)

  • 1. Prediction of amyloid positron emission tomography positivity using multiple regression analysis of quantitative susceptibility mapping.
    Ikebe Y; Sato R; Amemiya T; Udo N; Matsushima M; Yabe I; Yamaguchi A; Sasaki M; Harada M; Matsukawa N; Kawata Y; Bito Y; Shirai T; Ochi H; Kudo K
    Magn Reson Imaging; 2023 Nov; 103():192-197. PubMed ID: 37558171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a difference in regional read [
    Farrar G; Molinuevo JL; Zanette M
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET/MRI study.
    Tiepolt S; Rullmann M; Jochimsen TH; Gertz HJ; Schroeter ML; Patt M; Sabri O; Barthel H
    Eur J Radiol; 2020 Oct; 131():109243. PubMed ID: 32916411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.
    van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
    Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals.
    Jeong YJ; Yoon HJ; Kang DY; Park KW
    Ann Nucl Med; 2023 May; 37(5):271-279. PubMed ID: 36749463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance in detecting amyloid positivity between
    Cho SH; Choe YS; Kim YJ; Lee B; Kim HJ; Jang H; Kim JP; Jung YH; Kim SJ; Kim BC; Farrar G; Na DL; Moon SH; Seo SW
    Sci Rep; 2020 Nov; 10(1):19576. PubMed ID: 33177593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status.
    Kim KY; Park J; Jeong YH; Kim HJ; Lee E; Park JY; Kim E; Kim WJ
    Alzheimers Res Ther; 2022 Nov; 14(1):162. PubMed ID: 36324157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity.
    Park JE; Yun J; Kim SJ; Shim WH; Oh JS; Oh M; Roh JH; Seo SW; Oh SJ; Kim JS
    PLoS One; 2019; 14(12):e0226265. PubMed ID: 31834916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.